Drug Profile
Research programme: BRAF V600E degradation therapeutics - C4 Therapeutics
Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator C4 Therapeutics
- Developer C4 Therapeutics; Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Solid-tumours in USA (PO)
- 10 Nov 2021 C4T and Roche mutually agreed to terminate their agreement solely with respect to the BRAF target therapeutics for Cancer
- 11 Mar 2021 C4 Therapeutics announces intention to initiate IND enabling studies in 2021